

ATAGI recommendation for using cell-derived influenza vaccine versus standard dose egg-based influenza vaccine in children aged 2–17 years

There is no preferential recommendation between the use of cell-derived influenza vaccine (cIV) and standard dose egg-based influenza vaccine (sIV) in children aged 2–17 years.

Justification

- The direction of the effect was generally slightly favourable to cIV than sIV for a range of influenza-related outcomes. However, there is currently insufficient certainty in the evidence to demonstrate cIV is more effective than sIV against influenza.
- Compared with sIV, cIV results in a very small increase in local adverse events, but there is little to no difference in systemic adverse events, serious adverse events or adverse events of special interest caused by both vaccines.

Note: NCIRS is conducting GRADE in support of ATAGI and making results available on the NCIRS website. Please read this document as a supplement to the [Australian Immunisation Handbook Influenza disease chapter](#) and the [ATAGI Annual Influenza Statement](#).